Your biweekly update on health economics, policy, and impact
The rules of drug pricing are rapidly changing. In this Bulletin, we follow MFN from Washington to Berlin to London, and ask whether the QALY should really get the last word.
That’s your Bulletin summary, or read on for the full stories below.
Brittany Darrow,
Economist
MFN’s ripple effects are reaching Europe
The US’s Most-Favoured-Nation (MFN) pricing policy is often presented as a mechanism to reduce US drug prices, but a critical objective is also to increase what other countries pay for medicines and, therefore, innovation.
MFN’s reach, consequently, extends well beyond US borders. Our new framework illustrates its global impact, highlighting potential effects on manufacturers, payers, policymakers and patients and how they may respond.
MFN’s impact is already visible in Europe. Germany is in the crosshairs: the US is pushing for increased pharmaceutical spending through a Section 301 investigation. Yet, Germany faces a significant health insurance deficit, which has incentivised policymakers to reduce medicine expenditure—the opposite of MFN’s aim.
The UK has agreed to (implicitly) higher pharmaceutical prices and increased medicine spending in return for zero US tariffs on pharmaceuticals. Our takeaway is that policymakers are increasingly weighing industrial strategy and economic growth alongside health when shaping pharmaceutical policy.
The UK and Germany show how MFN is playing out in different ways—it remains to be seen how the rest of Europe will respond.
Who pays when America pays less?
MFN’s global ripple effects: what they mean for manufacturers, payers, patients and policymakers
In May 2025, the US introduced Most-Favoured Nation (MFN) pricing for branded medicines. Our new framework maps its global ripple effects across manufacturers, payers, patients and policymakers, from delayed launches and pressure on willingness-to-pay to trade deals and shifting R&D investment. Every group’s move affects the others, so no country is sheltered from the fallout. And if launches slow down, patients will feel it first.
Germany in the crosshairs: The latest on MFN pricing
Germany is one of Europe’s biggest players in life sciences, and the US is now putting pressure on it through a Section 301 investigation. In this bonus episode of A Dose of Economics, Grace Hampson and Graham Cookson unpack what that means for German pricing and investment. They also look at what two newly published pharma deals with the US government tell us about MFN’s real aims.
Beyond opportunity cost: what are health systems for? The UK–US pharmaceutical agreement and the limits of QALY maximisation
The near-term commitment is modest, with medicines spending rising by roughly £1.7bn a year by 2028. In return, the UK secured zero US tariffs for a sector exporting almost £25bn a year. The much larger headline figures rely on future governments holding to a decade-long path. Graham Cookson looks at what’s actually been agreed, and what the critics get right.
How Are JCA and the EU Pharma Package Changing the Economics of Drug Development?
A Perspective from Graham Cookson
From earlier evidence planning under JCA to proposed changes in data and market protection, the rules of drug development in Europe are changing. Graham Cookson talks Mel Whittington oh her Perspectives podcast through what this means for orphan drugs, breakthrough products and areas of unmet need, and where MFN pricing fits in.